Data show MammaPrintยฎย is the first and most comprehensive FDA-cleared test Read More
Data demonstrate Research Use Only ImPrint testโs ability to identify Read More
Company to present multiple recent Registry sub-studies driving cancer care Read More
Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing Read More
Company showcases pipeline developments and sub-studies from the revolutionary FLEX Read More
January 27, 2022 By Leo OโConnor NEW YORK โย As part Read More
New analysis in peer-reviewed journal Genes, Chromosomes and Cancer Read More
AI solution will expand Agendiaโs testing platform in the Brazilian Read More
Multi-year partnership to advance the use of next-generation sequencing for Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ January 6, 2022 Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
ยฉ2025 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
CHIEF COMPLIANCE OFFICER
Stephanie has worked in compliance since 2005 and has extensive experience developing and managing programs to support compliance with global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining Agendia, Stephanie spent a significant portion of her career serving as a compliance officer in laboratories, such as HealthTrackRx, NeoGenomics, and Myriad Genetics, and held compliance leadership roles in medical device, pharma, and large health systems.
Stephanie graduated Summa Cum Laude with a B.S. in Healthcare Administration from Northern Illinois University and is Certified in Healthcare Compliance (CHC), Data Privacy (CHP), Research Compliance (CHRC), and is a Certified Internal Auditor (CIA).
